Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review

Guillaume Marquis-Gravel, David J. Moliterno, Darrel P. Francis, Peter Jüni, Yves D. Rosenberg, Bimmer E. Claessen, Robert J. Mentz, Roxana Mehran, Donald E. Cutlip, Cynthia Chauhan, Susan Quella, Faiez Zannad, Shaun G. Goodman

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

The role of percutaneous coronary interventions in addition to medical therapy for patients with stable coronary artery disease continues to be debated in routine clinical practice, despite more than 2 decades of randomized controlled trials. The residual uncertainty arises from particular challenges facing revascularization trials. Which endpoint do doctors care about, and which do patients care about? Which participants should be enrolled? What background medical therapy should we use? When is placebo control relevant? In this paper, we discuss how these questions can be approached and examine the merits and disadvantages of possible options. Engaging multiple stakeholders, including patients, researchers, regulators, and funders, to ensure the design elements are methodologically valid and clinically meaningful should be an aspirational goal in the development of future trials.

Original languageEnglish
Pages (from-to)435-450
Number of pages16
JournalJournal of the American College of Cardiology
Volume76
Issue number4
DOIs
StatePublished - 28 Jul 2020

Keywords

  • coronary artery disease
  • methods
  • percutaneous coronary intervention
  • randomized controlled trials

Fingerprint

Dive into the research topics of 'Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review'. Together they form a unique fingerprint.

Cite this